Exciting things are happening every day at VCU Massey Cancer Center. We’re saving lives and reducing suffering from cancer. We’re discovering new and better ways to prevent, diagnose and treat cancer. We’re offering opportunities for the community to join us in the progress against cancer.
Updates to outpatient care at Massey due to COVID-19
At VCU Massey Cancer Center we have implemented changes in our clinics to mitigate the coronavirus (COVID-19) situation and keep our patients and medical teams safe.
In his previous role at Moffitt Cancer Center, Said Sebti, Ph.D., the associate director for basic research at VCU Massey Cancer Center, and his collaborators discovered a novel drug called FGTI-2734 that overcomes a major hurdle in halting the growth of malignant tumors driven by the cancer-causing KRAS protein, including pancreatic cancer. In collaboration with Massey researchers and the Medicines for All Institute (M4ALL) at VCU, Sebti intends to further develop FGTI-2734 at Massey in an effort to eventually gain FDA approval for testing the drug in clinical trials.
VCU Massey Cancer Center was recently selected by The Sarcoma Alliance to join their global network of institutions specializing in the treatment of sarcoma, a rare cancer that affects the connective tissues. Massey is the organization’s first and only designated sarcoma center in Virginia.
A team of scientists, including VCU Massey Cancer Center researcher Masoud Manjili, D.V.M., Ph.D., conducted a comprehensive analysis of worldwide COVID-19 data to identify key strategies moving forward to develop effective therapeutics. In a critical literature review, among the 20 most-read articles published in the Journal of Immunology in May 2020, Manjili suggests that COVID-19 should be treated as an acute inflammatory disease and that severity of infection is associated with the dysregulation of inflammatory immune responses and subsequent inability to develop protective immunity from the virus.
$2.3 million grant from the National Cancer Institute funds new viral-based gene therapies for lung cancer at Massey
Mutations in the p53 gene are found in more than half of all cancers, yet it has proven to be very difficult to target the gene with therapeutic drugs even 40 years after its discovery. VCU Massey Cancer Center researchers Sumitra Deb, Ph.D., and Brad Windle, Ph.D., are hoping to turn the tide with an innovative viral-based strategy, and they recently received more than $2 million from the National Cancer Institute to fund their work.
Researchers at VCU Massey Cancer Center are adding to an expansive study called Together for Health – Virginia to better understand how residents in our state have been impacted by the COVID-19 pandemic. The program can be accessed through a mobile app available at the Apple App Story or Google Play (by searching Together for Health – Virginia) or online at Together for Health – Virginia.